

PRODUCT INFORMATION

Common Name	MOR208, XmAb5574, XmAb®5574, MOR-00208, MOR-208, XENP-5574, XMP-5574, XmAb-5574, Xmab-CD19, Xmab5574, tafasitamab-cxix
Conjugate	Unconjugated
Synonyms	CD19,B4,CVID3,MGC12802
Applications	ELISA
Recommended Dilutions	ELISA 1:5000-10000
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG1-G2 - kappa
Reactivity	Human
Target	CD19
Uniprot ID	P15391
Description	Anti-CD19(tafasitamab biosimilar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



**Anti-CD19(tafasitamab biosimilar) mAb ELISA**

0.2 µg of Human CD19 (M75I,L82V,F83L), hFc tagged protein per well




Figure 1. ELISA plate pre-coated by 2 µg/mL (100 µL/well) Human CD19(M75I,L82V,F83L), hFc Tag (PME101557) can bind Anti-CD19(tafasitamab biosimilar) mAb (BME100683) in a linear range of 3.2-80 ng/mL.

